JennetteJC: Overview of the 2012 revised International Chapel Hill Consensus Conference nomenclature of vasculitides. Clin Exp Nephrol17: 603–606, 2013PubMed
JennetteJC: Overview of the 2012 revised International Chapel Hill Consensus Conference nomenclature of vasculitides. Clin Exp Nephrol 17: 603–606, 2013PubMed)| false
RovinBH, AdlerSG, BarrattJ, et al.; Kidney Disease: Improving Global Outcomes (KDIGO) Glomerular Diseases Work Group: KDIGO 2021 clinical practice guideline for the management of glomerular diseases. Kidney Int100: S1–S276, 2021PubMed
RovinBH, AdlerSG, BarrattJ, ; Kidney Disease: Improving Global Outcomes (KDIGO) Glomerular Diseases Work Group: KDIGO 2021 clinical practice guideline for the management of glomerular diseases. Kidney Int 100: S1–S276, 2021PubMed)| false
ChungSA, LangfordCA, MazM, AbrilA, GorelikM, GuyattG, et al.: 2021 American College of Rheumatology/Vasculitis Foundation Guideline for the management of antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheumatol73: 1366–1383, 2021PubMed
ChungSA, LangfordCA, MazM, AbrilA, GorelikM, GuyattG, : 2021 American College of Rheumatology/Vasculitis Foundation Guideline for the management of antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheumatol 73: 1366–1383, 2021PubMed)| false
JennetteJC, FalkRJ, AndrassyK, BaconPA, ChurgJ, GrossWL, et al.: Nomenclature of systemic vasculitides. Proposal of an international consensus conference. Arthritis Rheum37: 187–192, 1994PubMed
HunderGG, ArendWP, BlochDA, CalabreseLH, FauciAS, FriesJF, et al.: The American College of Rheumatology 1990 criteria for the classification of vasculitis. Introduction. Arthritis Rheum33: 1065–1067, 1990PubMed
HunderGG, ArendWP, BlochDA, CalabreseLH, FauciAS, FriesJF, : The American College of Rheumatology 1990 criteria for the classification of vasculitis. Introduction. Arthritis Rheum 33: 1065–1067, 1990PubMed)| false
CravenA, RobsonJ, PonteC, GraysonPC, SuppiahR, JudgeA, et al.: ACR/EULAR-endorsed study to develop diagnostic and classification criteria for vasculitis (DCVAS). Clin Exp Nephrol17: 619–621, 2013PubMed
RobsonJC, GraysonPC, PonteC, SuppiahR, CravenA, JudgeA, et al.; DCVAS Investigators: 2022 American College of Rheumatology/European Alliance of Associations for Rheumatology classification criteria for granulomatosis with polyangiitis. Ann Rheum Dis81: 315–320, 2022PubMed
RobsonJC, GraysonPC, PonteC, SuppiahR, CravenA, JudgeA, ; DCVAS Investigators: 2022 American College of Rheumatology/European Alliance of Associations for Rheumatology classification criteria for granulomatosis with polyangiitis. Ann Rheum Dis 81: 315–320, 2022PubMed)| false
GraysonPC, PonteC, SuppiahR, RobsonJC, CravenA, JudgeA, et al.; DCVAS Study Group: 2022 American College of Rheumatology/European Alliance of Associations for Rheumatology classification criteria for eosinophilic granulomatosis with polyangiitis. Ann Rheum Dis81: 309–314, 2022PubMed
GraysonPC, PonteC, SuppiahR, RobsonJC, CravenA, JudgeA, ; DCVAS Study Group: 2022 American College of Rheumatology/European Alliance of Associations for Rheumatology classification criteria for eosinophilic granulomatosis with polyangiitis. Ann Rheum Dis 81: 309–314, 2022PubMed)| false
SuppiahR, RobsonJC, GraysonPC, PonteC, CravenA, KhalidS, et al.; DCVAS INVESTIGATORS: 2022 American College of Rheumatology/European Alliance of Associations for Rheumatology classification criteria for microscopic polyangiitis. Ann Rheum Dis81: 321–326, 2022PubMed
SuppiahR, RobsonJC, GraysonPC, PonteC, CravenA, KhalidS, ; DCVAS INVESTIGATORS: 2022 American College of Rheumatology/European Alliance of Associations for Rheumatology classification criteria for microscopic polyangiitis. Ann Rheum Dis 81: 321–326, 2022PubMed)| false
BossuytX, Cohen TervaertJW, ArimuraY, BlockmansD, Flores-SuárezLF, GuillevinL, et al.: Position paper: Revised 2017 international consensus on testing of ANCAs in granulomatosis with polyangiitis and microscopic polyangiitis. Nat Rev Rheumatol13: 683–692, 2017PubMed
BossuytX, Cohen TervaertJW, ArimuraY, BlockmansD, Flores-SuárezLF, GuillevinL, : Position paper: Revised 2017 international consensus on testing of ANCAs in granulomatosis with polyangiitis and microscopic polyangiitis. Nat Rev Rheumatol 13: 683–692, 2017PubMed)| false
van DaalenEE, Wester TrejoMAC, GöçeroğluA, FerrarioF, JohK, NoëlLH, et al.: Developments in the histopathological classification of ANCA-associated glomerulonephritis. Clin J Am Soc Nephrol15: 1103–1111, 2020PubMed
BrixSR, NoriegaM, TennstedtP, VettorazziE, BuschM, NitschkeM, et al.: Development and validation of a renal risk score in ANCA-associated glomerulonephritis. Kidney Int94: 1177–1188, 2018PubMed
BrixSR, NoriegaM, TennstedtP, VettorazziE, BuschM, NitschkeM, : Development and validation of a renal risk score in ANCA-associated glomerulonephritis. Kidney Int 94: 1177–1188, 2018PubMed)| false
NtatsakiE, CarruthersD, ChakravartyK, D’CruzD, HarperL, JayneD, et al.; BSR and BHPR Standards, Guidelines and Audit Working Group: BSR and BHPR guideline for the management of adults with ANCA-associated vasculitis. Rheumatology (Oxford)53: 2306–2309, 2014PubMed
NtatsakiE, CarruthersD, ChakravartyK, D’CruzD, HarperL, JayneD, ; BSR and BHPR Standards, Guidelines and Audit Working Group: BSR and BHPR guideline for the management of adults with ANCA-associated vasculitis. Rheumatology (Oxford) 53: 2306–2309, 2014PubMed)| false
YatesM, WattsRA, BajemaIM, CidMC, CrestaniB, HauserT, et al.: EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis. Ann Rheum Dis75: 1583–1594, 2016PubMed
De GrootK, RasmussenN, BaconPA, TervaertJW, FeigheryC, GregoriniG, et al.: Randomized trial of cyclophosphamide versus methotrexate for induction of remission in early systemic antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum52: 2461–2469, 2005PubMed
De GrootK, RasmussenN, BaconPA, TervaertJW, FeigheryC, GregoriniG, : Randomized trial of cyclophosphamide versus methotrexate for induction of remission in early systemic antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 52: 2461–2469, 2005PubMed)| false
HarperL, MorganMD, WalshM, HoglundP, WestmanK, FlossmannO, et al.; EUVAS investigators: Pulse versus daily oral cyclophosphamide for induction of remission in ANCA-associated vasculitis: Long-term follow-up. Ann Rheum Dis71: 955–960, 2012PubMed
StoneJH, MerkelPA, SpieraR, SeoP, LangfordCA, HoffmanGS, et al.; RAVE-ITN Research Group: Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med363: 221–232, 2010PubMed
StoneJH, MerkelPA, SpieraR, SeoP, LangfordCA, HoffmanGS, ; RAVE-ITN Research Group: Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med 363: 221–232, 2010PubMed)| false
JonesRB, TervaertJW, HauserT, LuqmaniR, MorganMD, PehCA, et al.; European Vasculitis Study Group: Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. N Engl J Med363: 211–220, 2010PubMed
JonesRB, TervaertJW, HauserT, LuqmaniR, MorganMD, PehCA, ; European Vasculitis Study Group: Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. N Engl J Med 363: 211–220, 2010PubMed)| false
JonesRB, HiemstraTF, BallarinJ, BlockmansDE, BroganP, BruchfeldA, et al.; European Vasculitis Study Group (EUVAS): Mycophenolate mofetil versus cyclophosphamide for remission induction in ANCA-associated vasculitis: A randomised, non-inferiority trial. Ann Rheum Dis78: 399–405, 2019PubMed
JonesRB, HiemstraTF, BallarinJ, BlockmansDE, BroganP, BruchfeldA, ; European Vasculitis Study Group (EUVAS): Mycophenolate mofetil versus cyclophosphamide for remission induction in ANCA-associated vasculitis: A randomised, non-inferiority trial. Ann Rheum Dis 78: 399–405, 2019PubMed)| false
TuinJ, StassenPM, BogdanDI, BroekroelofsJ, van PaassenP, Cohen TervaertJW, et al.: Mycophenolate mofetil versus cyclophosphamide for the induction of remission in nonlife-threatening relapses of antineutrophil cytoplasmic antibody-associated vasculitis: Randomized, controlled trial. Clin J Am Soc Nephrol14: 1021–1028, 2019PubMed
TuinJ, StassenPM, BogdanDI, BroekroelofsJ, van PaassenP, Cohen TervaertJW, : Mycophenolate mofetil versus cyclophosphamide for the induction of remission in nonlife-threatening relapses of antineutrophil cytoplasmic antibody-associated vasculitis: Randomized, controlled trial. Clin J Am Soc Nephrol 14: 1021–1028, 2019PubMed)| false
WalshM, MerkelPA, PehCA, SzpirtWM, PuéchalX, FujimotoS, et al.; PEXIVAS Investigators: Plasma exchange and glucocorticoids in severe ANCA-associated vasculitis. N Engl J Med382: 622–631, 2020PubMed
WalshM, MerkelPA, PehCA, SzpirtWM, PuéchalX, FujimotoS, ; PEXIVAS Investigators: Plasma exchange and glucocorticoids in severe ANCA-associated vasculitis. N Engl J Med 382: 622–631, 2020PubMed)| false
SpecksU, FussnerLA, Cartin-CebaR, Casal MouraM, ZandL, FervenzaFC: Plasma exchange for the management of ANCA-associated vasculitis: the con position. Nephrol Dial Transplant36: 231–236, 2021PubMed
SpecksU, FussnerLA, Cartin-CebaR, Casal MouraM, ZandL, FervenzaFC: Plasma exchange for the management of ANCA-associated vasculitis: the con position. Nephrol Dial Transplant 36: 231–236, 2021PubMed)| false
WalshM, CollisterD, ZengL, MerkelPA, PuseyCD, GuyattG, et al.; Plasma exchange and glucocorticoid dosing for patients with ANCA-associated vasculitis BMJ Rapid Recommendations Group: The effects of plasma exchange in patients with ANCA-associated vasculitis: An updated systematic review and meta-analysis. BMJ376: 064604, 2022PubMed
WalshM, CollisterD, ZengL, MerkelPA, PuseyCD, GuyattG, ; Plasma exchange and glucocorticoid dosing for patients with ANCA-associated vasculitis BMJ Rapid Recommendations Group: The effects of plasma exchange in patients with ANCA-associated vasculitis: An updated systematic review and meta-analysis. BMJ 376: 064604, 2022PubMed)| false
ZengL, WalshM, GuyattGH, SiemieniukRAC, CollisterD, BoothM, et al.: Plasma exchange and glucocorticoid dosing for patients with ANCA-associated vasculitis: A clinical practice guideline. BMJ376: 064597, 2022PubMed
NezamD, PorcherR, GrolleauF, MorelP, Titeca-BeauportD, FaguerS, et al.; French Vasculitis Study Group: Kidney histopathology can predict kidney function in ANCA-associated vasculitides with acute kidney injury treated with plasma exchanges. J Am Soc Nephrol33: 628–637, 2022PubMed
NezamD, PorcherR, GrolleauF, MorelP, Titeca-BeauportD, FaguerS, ; French Vasculitis Study Group: Kidney histopathology can predict kidney function in ANCA-associated vasculitides with acute kidney injury treated with plasma exchanges. J Am Soc Nephrol 33: 628–637, 2022PubMed)| false
FurutaS, NakagomiD, KobayashiY, HiraguriM, SugiyamaT, AmanoK, et al.; LoVAS Collaborators: Effect of reduced-dose vs high-dose glucocorticoids added to rituximab on remission induction in ANCA-associated vasculitis: A randomized clinical trial. JAMA325: 2178–2187, 2021PubMed
JayneDRW, MerkelPA, SchallTJ, BekkerP; ADVOCATE Study Group: Avacopan for the treatment of ANCA-associated vasculitis. N Engl J Med384: 599–609, 2021PubMed
JayneDRW, MerkelPA, SchallTJ, BekkerP; ADVOCATE Study Group: Avacopan for the treatment of ANCA-associated vasculitis. N Engl J Med 384: 599–609, 2021PubMed)| false
DhaunN, McAdooSP: The changing role of glucocorticoids in the treatment of anti-neutrophil cytoplasmic antibody-associated vasculitis. Kidney Int101: 201–204, 2022PubMed
DhaunN, McAdooSP: The changing role of glucocorticoids in the treatment of anti-neutrophil cytoplasmic antibody-associated vasculitis. Kidney Int 101: 201–204, 2022PubMed)| false
JayneDR, GaskinG, RasmussenN, AbramowiczD, FerrarioF, GuillevinL, et al.; European Vasculitis Study Group: Randomized trial of plasma exchange or high-dosage methylprednisolone as adjunctive therapy for severe renal vasculitis. J Am Soc Nephrol18: 2180–2188, 2007PubMed
JayneDR, GaskinG, RasmussenN, AbramowiczD, FerrarioF, GuillevinL, ; European Vasculitis Study Group: Randomized trial of plasma exchange or high-dosage methylprednisolone as adjunctive therapy for severe renal vasculitis. J Am Soc Nephrol 18: 2180–2188, 2007PubMed)| false
Casal MouraM, IrazabalMV, EirinA, ZandL, SethiS, BorahBJ, et al.: Efficacy of rituximab and plasma exchange in antineutrophil cytoplasmic antibody-associated vasculitis with severe kidney disease. J Am Soc Nephrol31: 2688–2704, 2020PubMed
Kidney Disease: Improving Global Outcomes (KDIGO) Glomerulonephritis Work Group: KDIGO Clinical Practice Guideline for Glomerulonephritis. Kidney Int Suppl2: 139–274, 2012
Kidney Disease: Improving Global Outcomes (KDIGO) Glomerulonephritis Work Group: KDIGO Clinical Practice Guideline for Glomerulonephritis. Kidney Int Suppl 2: 139–274, 2012)| false
JayneD, RasmussenN, AndrassyK, BaconP, TervaertJW, DadonienéJ, et al.; European Vasculitis Study Group: A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. N Engl J Med349: 36–44, 2003PubMed
JayneD, RasmussenN, AndrassyK, BaconP, TervaertJW, DadonienéJ, ; European Vasculitis Study Group: A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. N Engl J Med 349: 36–44, 2003PubMed)| false
HiemstraTF, WalshM, MahrA, SavageCO, de GrootK, HarperL, et al.; European Vasculitis Study Group (EUVAS): Mycophenolate mofetil vs azathioprine for remission maintenance in antineutrophil cytoplasmic antibody-associated vasculitis: A randomized controlled trial. JAMA304: 2381–2388, 2010PubMed
HiemstraTF, WalshM, MahrA, SavageCO, de GrootK, HarperL, ; European Vasculitis Study Group (EUVAS): Mycophenolate mofetil vs azathioprine for remission maintenance in antineutrophil cytoplasmic antibody-associated vasculitis: A randomized controlled trial. JAMA 304: 2381–2388, 2010PubMed)| false
KarrasA, PagnouxC, HaubitzM, GrootK, PuechalX, TervaertJWC, et al.; European Vasculitis Society: Randomised controlled trial of prolonged treatment in the remission phase of ANCA-associated vasculitis. Ann Rheum Dis76: 1662–1668, 2017PubMed
KarrasA, PagnouxC, HaubitzM, GrootK, PuechalX, TervaertJWC, ; European Vasculitis Society: Randomised controlled trial of prolonged treatment in the remission phase of ANCA-associated vasculitis. Ann Rheum Dis 76: 1662–1668, 2017PubMed)| false
GuillevinL, PagnouxC, KarrasA, KhouatraC, AumaîtreO, CohenP, et al.; French Vasculitis Study Group: Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis. N Engl J Med371: 1771–1780, 2014PubMed
GuillevinL, PagnouxC, KarrasA, KhouatraC, AumaîtreO, CohenP, ; French Vasculitis Study Group: Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis. N Engl J Med 371: 1771–1780, 2014PubMed)| false
TerrierB, PagnouxC, PerrodeauÉ, KarrasA, KhouatraC, AumaîtreO, et al.; French Vasculitis Study Group: Long-term efficacy of remission-maintenance regimens for ANCA-associated vasculitides. Ann Rheum Dis77: 1150–1156, 2018PubMed
CharlesP, TerrierB, PerrodeauÉ, CohenP, FaguerS, HuartA, et al.; French Vasculitis Study Group: Comparison of individually tailored versus fixed-schedule rituximab regimen to maintain ANCA-associated vasculitis remission: Results of a multicentre, randomised controlled, phase III trial (MAINRITSAN2). Ann Rheum Dis77: 1143–1149, 2018PubMed
CharlesP, TerrierB, PerrodeauÉ, CohenP, FaguerS, HuartA, ; French Vasculitis Study Group: Comparison of individually tailored versus fixed-schedule rituximab regimen to maintain ANCA-associated vasculitis remission: Results of a multicentre, randomised controlled, phase III trial (MAINRITSAN2). Ann Rheum Dis 77: 1143–1149, 2018PubMed)| false
CharlesP, PerrodeauÉ, SamsonM, BonnotteB, NéelA, AgardC, et al.; French Vasculitis Study Group: Long-term rituximab use to maintain remission of antineutrophil cytoplasmic antibody-associated vasculitis: A randomized trial. Ann Intern Med173: 179–187, 2020PubMed
CharlesP, PerrodeauÉ, SamsonM, BonnotteB, NéelA, AgardC, ; French Vasculitis Study Group: Long-term rituximab use to maintain remission of antineutrophil cytoplasmic antibody-associated vasculitis: A randomized trial. Ann Intern Med 173: 179–187, 2020PubMed)| false
van DamLS, DirikgilE, BredewoldEW, RayA, BakkerJA, van KootenC, et al.: Proteinase-3-anti-neutrophil cytoplasmic antibodies (PR3-ANCAs) predict relapses in ANCA-associated vasculitis patients after rituximab. Nephrol Dial Transplant36: 1408–1417, 2021
WallaceZS, FuX, HarknessT, StoneJH, ZhangY, ChoiH: All-cause and cause-specific mortality in ANCA-associated vasculitis: Overall and according to ANCA type. Rheumatology (Oxford)59: 2308–2315, 2019
WallaceZS, FuX, HarknessT, StoneJH, ZhangY, ChoiH: All-cause and cause-specific mortality in ANCA-associated vasculitis: Overall and according to ANCA type. Rheumatology (Oxford) 59: 2308–2315, 2019)| false
TanJA, DehghanN, ChenW, XieH, EsdaileJM, Avina-ZubietaJA: Mortality in ANCA-associated vasculitis: A meta-analysis of observational studies. Ann Rheum Dis76: 1566–1574, 2017PubMed
FlossmannO, BerdenA, de GrootK, HagenC, HarperL, HeijlC, et al.; European Vasculitis Study Group: Long-term patient survival in ANCA-associated vasculitis. Ann Rheum Dis70: 488–494, 2011PubMed
FlossmannO, BerdenA, de GrootK, HagenC, HarperL, HeijlC, ; European Vasculitis Study Group: Long-term patient survival in ANCA-associated vasculitis. Ann Rheum Dis 70: 488–494, 2011PubMed)| false
WakiD, NishimuraK, TokumasuH, KadobaK, MukoyamaH, SaitoR, et al.: Initial high-dose corticosteroids and renal impairment are risk factors for early severe infections in elderly patients with antineutrophil cytoplasmic autoantibody-associated vasculitis: A retrospective observational study. Medicine (Baltimore)99: 19173, 2020PubMed
WakiD, NishimuraK, TokumasuH, KadobaK, MukoyamaH, SaitoR, : Initial high-dose corticosteroids and renal impairment are risk factors for early severe infections in elderly patients with antineutrophil cytoplasmic autoantibody-associated vasculitis: A retrospective observational study. Medicine (Baltimore) 99: 19173, 2020PubMed)| false
WeinerM, GohSM, MohammadAJ, HruskovaZ, TannaA, BruchfeldA, et al.: Outcome and treatment of elderly patients with ANCA-associated vasculitis. Clin J Am Soc Nephrol10: 1128–1135, 2015PubMed
SebastianR, ArunachalamJ, RajendranM: Temporal clustering of antiglomerular basement membrane disease in COVID-19 pandemic: A case series. Int J Nephrol Renovasc Dis14: 393–398, 2021PubMed
SebastianR, ArunachalamJ, RajendranM: Temporal clustering of antiglomerular basement membrane disease in COVID-19 pandemic: A case series. Int J Nephrol Renovasc Dis 14: 393–398, 2021PubMed)| false
PokidyshevaEN, SeegerH, PedchenkoV, ChetyrkinS, BergmannC, AbrahamsonD, et al.: Collagen IVα345 dysfunction in glomerular basement membrane diseases. I. Discovery of a COL4A3 variant in familial Goodpasture’s and Alport diseases. J Biol Chem296: 100590, 2021PubMed
HuartA, JosseAG, ChauveauD, KorachJM, HeshmatiF, BauvinE, et al.; French Society of Hemapheresis: Outcomes of patients with Goodpasture syndrome: A nationwide cohort-based study from the French Society of Hemapheresis. J Autoimmun73: 24–29, 2016PubMed
HuartA, JosseAG, ChauveauD, KorachJM, HeshmatiF, BauvinE, ; French Society of Hemapheresis: Outcomes of patients with Goodpasture syndrome: A nationwide cohort-based study from the French Society of Hemapheresis. J Autoimmun 73: 24–29, 2016PubMed)| false
MarquesC, CarvelliJ, BiardL, FaguerS, ProvôtF, MatignonM, et al.: Prognostic factors in anti-glomerular basement membrane disease: A multicenter study of 119 patients. Front Immunol10: 1665, 2019PubMed
JiaXY, XuHY, JiaXY, CuiZ, ZhaoMH: Predictors of kidney outcomes of anti-glomerular basement membrane disease in a large Chinese cohort. Am J Nephrol53: 397–406, 2022PubMed
JiaXY, XuHY, JiaXY, CuiZ, ZhaoMH: Predictors of kidney outcomes of anti-glomerular basement membrane disease in a large Chinese cohort. Am J Nephrol 53: 397–406, 2022PubMed)| false
van DaalenEE, JennetteJC, McAdooSP, PuseyCD, AlbaMA, PoultonCJ, et al.: Predicting outcome in patients with anti-GBM glomerulonephritis. Clin J Am Soc Nephrol13: 63–72, 2018PubMed
UhlinF, SzpirtW, KronbichlerA, BruchfeldA, SoveriI, RostaingL, et al.: Endopeptidase cleavage of anti-glomerular basement membrane antibodies in vivo in severe kidney disease: An open-label phase 2a study. J Am Soc Nephrol33: 829–838, 2022PubMed
UhlinF, SzpirtW, KronbichlerA, BruchfeldA, SoveriI, RostaingL, : Endopeptidase cleavage of anti-glomerular basement membrane antibodies in vivo in severe kidney disease: An open-label phase 2a study. J Am Soc Nephrol 33: 829–838, 2022PubMed)| false
McAdooSP, TannaA, HruškováZ, HolmL, WeinerM, ArulkumaranN, et al.: Patients double-seropositive for ANCA and anti-GBM antibodies have varied renal survival, frequency of relapse, and outcomes compared to single-seropositive patients. Kidney Int92: 693–702, 2017PubMed
McAdooSP, TannaA, HruškováZ, HolmL, WeinerM, ArulkumaranN, : Patients double-seropositive for ANCA and anti-GBM antibodies have varied renal survival, frequency of relapse, and outcomes compared to single-seropositive patients. Kidney Int 92: 693–702, 2017PubMed)| false
ShenCR, JiaXY, LuoW, OlaruF, CuiZ, ZhaoMH, et al.: Laminin-521 is a novel target of autoantibodies associated with lung hemorrhage in anti-GBM disease. J Am Soc Nephrol32: 1887–1897, 2021PubMed
ShenCR, JiaXY, LuoW, OlaruF, CuiZ, ZhaoMH, : Laminin-521 is a novel target of autoantibodies associated with lung hemorrhage in anti-GBM disease. J Am Soc Nephrol 32: 1887–1897, 2021PubMed)| false
ShenCR, JiaXY, CuiZ, YuXJ, ZhaoMH: Clinical-pathological features and outcome of atypical anti-glomerular basement membrane disease in a large single cohort. Front Immunol11: 2035, 2020PubMed
ShenCR, JiaXY, CuiZ, YuXJ, ZhaoMH: Clinical-pathological features and outcome of atypical anti-glomerular basement membrane disease in a large single cohort. Front Immunol 11: 2035, 2020PubMed)| false
RosalesIA, ColvinRB: Glomerular disease with idiopathic linear immunoglobulin deposition: a rose by any other name would be atypical. Kidney Int89: 750–752, 2016PubMed
RosalesIA, ColvinRB: Glomerular disease with idiopathic linear immunoglobulin deposition: a rose by any other name would be atypical. Kidney Int 89: 750–752, 2016PubMed)| false
SalamaAD, DouganT, LevyJB, CookHT, MorganSH, NaudeerS, et al.: Goodpasture’s disease in the absence of circulating anti-glomerular basement membrane antibodies as detected by standard techniques. Am J Kidney Dis39: 1162–1167, 2002PubMed
SalamaAD, DouganT, LevyJB, CookHT, MorganSH, NaudeerS, : Goodpasture’s disease in the absence of circulating anti-glomerular basement membrane antibodies as detected by standard techniques. Am J Kidney Dis 39: 1162–1167, 2002PubMed)| false
HahnBH, McMahonMA, WilkinsonA, WallaceWD, DaikhDI, FitzgeraldJD, et al.; American College of Rheumatology: American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis. Arthritis Care Res (Hoboken)64: 797–808, 2012PubMed
HahnBH, McMahonMA, WilkinsonA, WallaceWD, DaikhDI, FitzgeraldJD, ; American College of Rheumatology: American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis. Arthritis Care Res (Hoboken) 64: 797–808, 2012PubMed)| false
GordonC, Amissah-ArthurMB, GayedM, BrownS, BruceIN, D’CruzD, et al.; British Society for Rheumatology Standards, Audit and Guidelines Working Group: The British Society for Rheumatology guideline for the management of systemic lupus erythematosus in adults. Rheumatology (Oxford)57: e1–e45, 2018PubMed
GordonC, Amissah-ArthurMB, GayedM, BrownS, BruceIN, D’CruzD, ; British Society for Rheumatology Standards, Audit and Guidelines Working Group: The British Society for Rheumatology guideline for the management of systemic lupus erythematosus in adults. Rheumatology (Oxford) 57: e1–e45, 2018PubMed)| false
FanouriakisA, KostopoulouM, CheemaK, AndersHJ, AringerM, BajemaI, et al.: 2019 Update of the Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of lupus nephritis. Ann Rheum Dis79: 713–723, 2020PubMed
FanouriakisA, KostopoulouM, CheemaK, AndersHJ, AringerM, BajemaI, : 2019 Update of the Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of lupus nephritis. Ann Rheum Dis 79: 713–723, 2020PubMed)| false
ManingdingE, Dall'EraM, TrupinL, MurphyLB, YazdanyJ: Racial/ethnic differences in prevalence of and time to onset of SLE manifestations: The California Lupus Surveillance Project (CLSP). Arthritis Care Res (Hoboken)72: 622–629, 2020
ManingdingE, Dall'EraM, TrupinL, MurphyLB, YazdanyJ: Racial/ethnic differences in prevalence of and time to onset of SLE manifestations: The California Lupus Surveillance Project (CLSP). Arthritis Care Res (Hoboken) 72: 622–629, 2020)| false
MoroniG, VercelloniPG, QuagliniS, GattoM, GianfredaD, SacchiL, et al.: Changing patterns in clinical-histological presentation and renal outcome over the last five decades in a cohort of 499 patients with lupus nephritis. Ann Rheum Dis77: 1318–1325, 2018PubMed
MoroniG, VercelloniPG, QuagliniS, GattoM, GianfredaD, SacchiL, : Changing patterns in clinical-histological presentation and renal outcome over the last five decades in a cohort of 499 patients with lupus nephritis. Ann Rheum Dis 77: 1318–1325, 2018PubMed)| false
BajemaIM, WilhelmusS, AlpersCE, BruijnJA, ColvinRB, CookHT, et al.: Revision of the International Society of Nephrology/Renal Pathology Society classification for lupus nephritis: Clarification of definitions, and modified National Institutes of Health activity and chronicity indices. Kidney Int93: 789–796, 2018PubMed
BajemaIM, WilhelmusS, AlpersCE, BruijnJA, ColvinRB, CookHT, : Revision of the International Society of Nephrology/Renal Pathology Society classification for lupus nephritis: Clarification of definitions, and modified National Institutes of Health activity and chronicity indices. Kidney Int 93: 789–796, 2018PubMed)| false
De RosaM, AzzatoF, ToblliJE, De RosaG, FuentesF, NagarajaHN, et al.: A prospective observational cohort study highlights kidney biopsy findings of lupus nephritis patients in remission who flare following withdrawal of maintenance therapy. Kidney Int94: 788–794, 2018PubMed
De RosaM, AzzatoF, ToblliJE, De RosaG, FuentesF, NagarajaHN, : A prospective observational cohort study highlights kidney biopsy findings of lupus nephritis patients in remission who flare following withdrawal of maintenance therapy. Kidney Int 94: 788–794, 2018PubMed)| false
Turner-StokesT, WilsonHR, MorrealeM, NunesA, CairnsT, CookHT, et al.: Positive antineutrophil cytoplasmic antibody serology in patients with lupus nephritis is associated with distinct histopathologic features on renal biopsy. Kidney Int92: 1223–1231, 2017PubMed
Turner-StokesT, WilsonHR, MorrealeM, NunesA, CairnsT, CookHT, : Positive antineutrophil cytoplasmic antibody serology in patients with lupus nephritis is associated with distinct histopathologic features on renal biopsy. Kidney Int 92: 1223–1231, 2017PubMed)| false
Bourse ChalvonN, OrquevauxP, GiustiD, GatouillatG, TabaryT, Tonye LibyhM, et al.: Absence of anti-glomerular basement membrane antibodies in 200 patients with systemic lupus erythematosus with or without lupus nephritis: Results of the GOODLUPUS Study. Front Immunol11: 597863, 2020PubMed
Bourse ChalvonN, OrquevauxP, GiustiD, GatouillatG, TabaryT, Tonye LibyhM, : Absence of anti-glomerular basement membrane antibodies in 200 patients with systemic lupus erythematosus with or without lupus nephritis: Results of the GOODLUPUS Study. Front Immunol 11: 597863, 2020PubMed)| false
MackayM, Dall’EraM, FishbeinJ, KalunianK, LesserM, Sanchez-GuerreroJ, et al.: Establishing surrogate kidney end points for lupus nephritis clinical trials: Development and validation of a novel approach to predict future kidney outcomes. Arthritis Rheumatol71: 411–419, 2019PubMed
MackayM, Dall’EraM, FishbeinJ, KalunianK, LesserM, Sanchez-GuerreroJ, : Establishing surrogate kidney end points for lupus nephritis clinical trials: Development and validation of a novel approach to predict future kidney outcomes. Arthritis Rheumatol 71: 411–419, 2019PubMed)| false
LiuZ, ZhangH, LiuZ, XingC, FuP, NiZ, et al.: Multitarget therapy for induction treatment of lupus nephritis: A randomized trial. Ann Intern Med162: 18–26, 2015PubMed
LiuZ, ZhangH, LiuZ, XingC, FuP, NiZ, : Multitarget therapy for induction treatment of lupus nephritis: A randomized trial. Ann Intern Med 162: 18–26, 2015PubMed)| false
RovinBH, SolomonsN, PendergraftWF3rd, DooleyMA, TumlinJ, Romero-DiazJ, et al.; AURA-LV Study Group: A randomized, controlled double-blind study comparing the efficacy and safety of dose-ranging voclosporin with placebo in achieving remission in patients with active lupus nephritis. Kidney Int95: 219–231, 2019PubMed
RovinBH, SolomonsN, PendergraftWF3rd, DooleyMA, TumlinJ, Romero-DiazJ, ; AURA-LV Study Group: A randomized, controlled double-blind study comparing the efficacy and safety of dose-ranging voclosporin with placebo in achieving remission in patients with active lupus nephritis. Kidney Int 95: 219–231, 2019PubMed)| false
CondonMB, AshbyD, PepperRJ, CookHT, LevyJB, GriffithM, et al.: Prospective observational single-centre cohort study to evaluate the effectiveness of treating lupus nephritis with rituximab and mycophenolate mofetil but no oral steroids. Ann Rheum Dis72: 1280–1286, 2013PubMed
CondonMB, AshbyD, PepperRJ, CookHT, LevyJB, GriffithM, : Prospective observational single-centre cohort study to evaluate the effectiveness of treating lupus nephritis with rituximab and mycophenolate mofetil but no oral steroids. Ann Rheum Dis 72: 1280–1286, 2013PubMed)| false
PepperR, GriffithM, KirwanC, LevyJ, TaubeD, PuseyC, et al.: Rituximab is an effective treatment for lupus nephritis and allows a reduction in maintenance steroids. Nephrol Dial Transplant24: 3717–3723, 2009PubMed
PepperR, GriffithM, KirwanC, LevyJ, TaubeD, PuseyC, : Rituximab is an effective treatment for lupus nephritis and allows a reduction in maintenance steroids. Nephrol Dial Transplant 24: 3717–3723, 2009PubMed)| false
RovinBH, FurieR, LatinisK, LooneyRJ, FervenzaFC, Sanchez-GuerreroJ, et al.; LUNAR Investigator Group: Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: The Lupus Nephritis Assessment with Rituximab study. Arthritis Rheum64: 1215–1226, 2012PubMed
RovinBH, FurieR, LatinisK, LooneyRJ, FervenzaFC, Sanchez-GuerreroJ, ; LUNAR Investigator Group: Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: The Lupus Nephritis Assessment with Rituximab study. Arthritis Rheum 64: 1215–1226, 2012PubMed)| false
Gomez MendezLM, CascinoMD, GargJ, KatsumotoTR, BrakemanP, Dall’EraM, et al.: Peripheral blood B cell depletion after rituximab and complete response in lupus nephritis. Clin J Am Soc Nephrol13: 1502–1509, 2018PubMed
ChavarotN, VerhelstD, PardonA, CaudwellV, MercadalL, SacchiA, et al.; Groupe Coopératif sur le Lupus Rénal: Rituximab alone as induction therapy for membranous lupus nephritis: A multicenter retrospective study. Medicine (Baltimore)96: e7429, 2017PubMed
ChavarotN, VerhelstD, PardonA, CaudwellV, MercadalL, SacchiA, ; Groupe Coopératif sur le Lupus Rénal: Rituximab alone as induction therapy for membranous lupus nephritis: A multicenter retrospective study. Medicine (Baltimore) 96: e7429, 2017PubMed)| false
FurieRA, ArocaG, CascinoMD, GargJP, RovinBH, AlvarezA, et al.: B-cell depletion with obinutuzumab for the treatment of proliferative lupus nephritis: A randomised, double-blind, placebo-controlled trial. Ann Rheum Dis81: 100–107, 2022PubMed
FurieRA, ArocaG, CascinoMD, GargJP, RovinBH, AlvarezA, : B-cell depletion with obinutuzumab for the treatment of proliferative lupus nephritis: A randomised, double-blind, placebo-controlled trial. Ann Rheum Dis 81: 100–107, 2022PubMed)| false
MyslerEF, SpindlerAJ, GuzmanR, BijlM, JayneD, FurieRA, et al.: Efficacy and safety of ocrelizumab in active proliferative lupus nephritis: Results from a randomized, double-blind, phase III study. Arthritis Rheum65: 2368–2379, 2013PubMed
MyslerEF, SpindlerAJ, GuzmanR, BijlM, JayneD, FurieRA, : Efficacy and safety of ocrelizumab in active proliferative lupus nephritis: Results from a randomized, double-blind, phase III study. Arthritis Rheum 65: 2368–2379, 2013PubMed)| false
NavarraSV, GuzmánRM, GallacherAE, HallS, LevyRA, JimenezRE, et al.; BLISS-52 Study Group: Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: A randomised, placebo-controlled, phase 3 trial. Lancet377: 721–731, 2011PubMed
NavarraSV, GuzmánRM, GallacherAE, HallS, LevyRA, JimenezRE, ; BLISS-52 Study Group: Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: A randomised, placebo-controlled, phase 3 trial. Lancet 377: 721–731, 2011PubMed)| false
FurieR, PetriM, ZamaniO, CerveraR, WallaceDJ, TegzováD, et al.; BLISS-76 Study Group: A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheum63: 3918–3930, 2011PubMed
FurieR, PetriM, ZamaniO, CerveraR, WallaceDJ, TegzováD, ; BLISS-76 Study Group: A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheum 63: 3918–3930, 2011PubMed)| false
RovinBH, FurieR, TengYKO, ContrerasG, MalvarA, YuX, et al.: A secondary analysis of the Belimumab International Study in Lupus Nephritis trial examined effects of belimumab on kidney outcomes and preservation of kidney function in patients with lupus nephritis. Kidney Int101: 403–413, 2022PubMed
RovinBH, FurieR, TengYKO, ContrerasG, MalvarA, YuX, : A secondary analysis of the Belimumab International Study in Lupus Nephritis trial examined effects of belimumab on kidney outcomes and preservation of kidney function in patients with lupus nephritis. Kidney Int 101: 403–413, 2022PubMed)| false
KraaijT, KamerlingSWA, de RooijENM, van DaelePLA, BredewoldOW, BakkerJA, et al.: The NET-effect of combining rituximab with belimumab in severe systemic lupus erythematosus. J Autoimmun91: 45–54, 2018PubMed
KraaijT, KamerlingSWA, de RooijENM, van DaelePLA, BredewoldOW, BakkerJA, : The NET-effect of combining rituximab with belimumab in severe systemic lupus erythematosus. J Autoimmun 91: 45–54, 2018PubMed)| false
FurieRA, MorandEF, BruceIN, ManziS, KalunianKC, VitalEW, et al.: Type I interferon inhibitor anifrolumab in active systemic lupus erythematosus (TULIP-1): A randomised, controlled, phase 3 trial. Lancet Rheumatol1: 208–219, 2019
MorandEF, FurieR, TanakaY, BruceIN, AskanaseAD, RichezC, et al.; TULIP-2 Trial Investigators: Trial of anifrolumab in active systemic lupus erythematosus. N Engl J Med382: 211–221, 2020PubMed
JayneD, RovinB, MyslerEF, FurieRA, HoussiauFA, TrasievaT, et al.: Phase II randomised trial of type I interferon inhibitor anifrolumab in patients with active lupus nephritis. Ann Rheum Dis81: 496–506, 2022PubMed
JayneD, RovinB, MyslerEF, FurieRA, HoussiauFA, TrasievaT, : Phase II randomised trial of type I interferon inhibitor anifrolumab in patients with active lupus nephritis. Ann Rheum Dis 81: 496–506, 2022PubMed)| false
FeltenR, SagezF, GavandPE, MartinT, KorganowAS, SordetC, et al.: 10 most important contemporary challenges in the management of SLE. Lupus Sci Med6: 000303, 2019PubMed
FeltenR, SagezF, GavandPE, MartinT, KorganowAS, SordetC, : 10 most important contemporary challenges in the management of SLE. Lupus Sci Med 6: 000303, 2019PubMed)| false